TABLE 3.
Summary of sensitivity and specificity for common methods of pelvic mass risk assessment.
| Imaging | Biomarker-based Assays | |||||||
|
|
|
|||||||
| TVUS (Subjective Assessment)* (67) | PET/CT (68) | MRI (69) | IOTA SR** (18, 67) | CA125*** (70, 71) | ROMA (44) | MIA (OVA1) (72) | MIA2G (Overa) (55) | |
| Guideline-recommended use (1) | Initial assessment and characterization | Additional characterization of high risk cases | Characterization of indeterminate masses | Initial assessment and characterization | Aid in risk assessment, guide decision to refer to gynecologic oncologist | N/A, not in 2016 ACOG guidelines | ||
| Sensitivity | ||||||||
| All malignancies | 73.0–100.0 | 58.0 | 91.0 | 91.0 | 77.0 | 84.9 | 92.2 | 91.3 |
| Early stage | − | − | − | 66.0 | 50.0 | 75.0 | 91.9 | 88.6 |
| Pre-menopausal | − | − | − | 89.0 | 62.5 | 67.5 | 89.5 | 90.3 |
| Post-menopausal | − | − | − | 92.0 | 80.1 | 90.8 | 93.3 | 91.8 |
| Specificity | ||||||||
| All malignancies | 43.0–99.0 | 76.0 | 91.0 | 91.0 | 93.8 | 79.7 | 49.4 | 69.1 |
*Range from meta-analysis. **Pooled value from meta-analysis. Indeterminate results had subjective assessment applied. ***Study PI used age </≥ 50 rather than menopausal status. Cutoff value was 35 U/mL for both age groups.